Evaluation of vascular endothelial growth factor as a prognostic marker for local relapse in early-stage breast cancer patients treated with breast-conserving therapy

International Journal of Radiation Oncology Biology Physics

Volumn 81, Issue 5, 2011, Pages 1236-1243

  Moran, Meena S ^a   Yang, Qifeng ^b,c   Goyal, Sharad ^b   Harris, Lyndsay ^a   Chung, Gina ^a   Haffty, Bruce G ^b  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b ROBERT WOOD JOHNSON MEDICAL SCHOOL   (United States)

^c SHANDONG UNIVERSITY   (China)

Author keywords

Breast cancer; Breast conserving therapy; Local relapse; Molecular markers; Vascular endothelial growth factor; VEGF

Indexed keywords

BREAST CANCER; BREAST-CONSERVING THERAPY; LOCAL RELAPSE; MOLECULAR MARKERS; VASCULAR ENDOTHELIAL GROWTH FACTOR; VEGF;

DIAGNOSIS; DISEASE CONTROL; DISEASES; GROWTH (MATERIALS); MULTIVARIANT ANALYSIS; PARAFFIN WAXES; PARAFFINS; PATHOLOGY; PATIENT MONITORING; PEPTIDES; TISSUE;

PATIENT TREATMENT;

EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; PROGESTERONE RECEPTOR; VASCULOTROPIN;

ADULT; AGED; ARTICLE; BREAST CANCER; BREAST CONSERVING THERAPY; CANCER PATIENT; CANCER RELAPSE; CANCER STAGING; CANCER THERAPY; CLINICAL FEATURE; CONTROLLED STUDY; EVALUATION; FAMILY HISTORY; FOLLOW UP; GENE OVEREXPRESSION; HUMAN; INSTITUTIONAL REVIEW; MAJOR CLINICAL STUDY; METASTASIS FREE SURVIVAL; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PATHOLOGY; PRACTICE GUIDELINE; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; RELAPSE FREE SURVIVAL; SURVIVAL; TISSUE MICROARRAY; TUMOR VOLUME;

ADULT; AFRICAN CONTINENTAL ANCESTRY GROUP; AGED; AGED, 80 AND OVER; ANALYSIS OF VARIANCE; BREAST NEOPLASMS; DISEASE-FREE SURVIVAL; EUROPEAN CONTINENTAL ANCESTRY GROUP; FEMALE; FOLLOW-UP STUDIES; HUMANS; MASTECTOMY, SEGMENTAL; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; PROGNOSIS; RADIOTHERAPY; TISSUE ARRAY ANALYSIS; TUMOR MARKERS, BIOLOGICAL; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 81855163409     PISSN: 03603016     EISSN: 1879355X     Source Type: Journal    
DOI: 10.1016/j.ijrobp.2010.07.031     Document Type: Article

References (42)

1. D. Hanahan, and R.A. Weinberg The hallmarks of cancer Cell 100 2000 57 70 (Pubitemid 30046295)
2. B.I. Rini, and E.J. Small Biology and clinical development of vascular endothelial growth factor-targeted therapy in renal cell carcinoma J Clin Oncol 23 2005 1028 1043 (Pubitemid 46202321)
3. S.E. Aldridge, T.W. Lennard, and J.R. Williams Vascular endothelial growth factor receptors in osteoclast differentiation and function Biochem Biophys Res Commun 335 2005 793 798 (Pubitemid 41188268)
4. L.A. Hefler, A. Mustea, and D. Konsgen Vascular endothelial growth factor gene polymorphisms are associated with prognosis in ovarian cancer Clin Cancer Res 13 2007 898 901 (Pubitemid 46340365)
5. S. Ramakrishnan, I.V. Subramanian, and Y. Yokoyama Angiogenesis in normal and neoplastic ovaries Angiogenesis 8 2005 169 182 (Pubitemid 41712846)
6. N. Ferrara, J. LeCouter, and R. Lin EG-VEGF and Bv8: A novel family of tissue-restricted angiogenic factors Biochim Biophys Acta 1654 2004 69 78 (Pubitemid 38230932)
7. R.K. Jain Normalization of tumor vasculature: An emerging concept in antiangiogenic therapy Science 307 2005 58 62 (Pubitemid 40093472)
8. G. Gasparini, M. Toi, and M. Gion Prognostic significance of vascular endothelial growth factor protein in node-negative breast carcinoma J Natl Cancer Inst 89 1997 139 147 (Pubitemid 27034790)
9. J.A. Foekens, H.A. Peters, and N. Grebenchtchikov High tumor levels of vascular endothelial growth factor predict poor response to systemic therapy in advanced breast cancer Cancer Res 61 2001 5407 5414 (Pubitemid 32694919)
10. G.E. Konecny, Y.G. Meng, and M. Untch Association between HER-2/neu and vascular endothelial growth factor expression predicts clinical outcome in primary breast cancer patients Clin Cancer Res 10 2004 1706 1716 (Pubitemid 38435562)
11. B. Linderholm, K. Grankvist, and N. Wilking Correlation of vascular endothelial growth factor content with recurrences, survival, and first relapse site in primary node-positive breast carcinoma after adjuvant treatment J Clin Oncol 18 2000 1423 1431 (Pubitemid 30205387)
12. H.J. Burstein, Y.-H. Chen, and L.M. Parker VEGF as a marker for outcome among advanced breast cancer patients receiving anti-VEGF therapy with bevacizumab and vinorelbine chemotherapy Clin Cancer Res 14 2008 7871 7877
13. G. Gasparini Prognostic value of vascular endothelial growth factor in breast cancer Oncologist 5 2000 37 44 (Pubitemid 30225456)
14. B. Linderholm, B. Tavelin, and K. Grankvist Vascular endothelial growth factor is of high prognostic value in node-negative breast carcinoma J Clin Oncol 16 1998 3121 3128 (Pubitemid 28417435)
15. G. Gasparini, M. Toi, and R. Miceli Clinical relevance of vascular endothelial growth factor and thymidine phosphorylase in patients with node-positive breast cancer treated with either adjuvant chemotherapy or hormone therapy Cancer J Sci Am 5 1999 101 111 (Pubitemid 29169299)
16. B.K. Linderholm, S. Gruvbreger-Saal, and M. Fernö Vascular endothelial growth factor is a strong predictor of early distant recurrences in a prospective study of premenopausal women with lymph-node negative breast cancer Breast 17 2008 484 491
17. B.K. Linderholm, H. Hellborg, and U. Johansson Significantly higher levels of vascular endothelial growth factor (VEGF) and shorter survival times for patients with primary operable triple-negative breast cancer Ann Oncol Epub 2009 June 23
18. B. Linderholm, J. Bergqvist, and H. Hellborg Shorter survival-times following adjuvant endocrine therapy in oestrogen- and progesterone-receptor positive breast cancer overexpressing HER2 and/or with an increased expression of vascular endothelial growth factor Med Oncol 26 2009 480 490
19. E. Mylona, P. Alexandrou, and I. Giannopoulou The prognostic value of vascular endothelial growth factors (VEGFs)-A and -B and their receptor, VEGFR-1, in invasive breast carcinoma Gynecol Oncol 104 2007 557 563
20. Taha FM, Zeeneldin AA, Helal AM, et al. Prognostic value of serum vascular endothelial growth factor in Egyptian females with metastatic triple negative breast cancer. Clin Biochem. In press.
21. E. Lund, A. Høg, and W. Olsen Differential regulation of VEGF, HIF1alpha and angiopoietin-1, -2 and -4 by hypoxia and ionizing radiation in human glioblastoma Int J Cancer 108 2004 833 838 (Pubitemid 38112610)
22. K.E. Hovinga, L.J. Stalpers, and C. van Bree Radiation-enhanced vascular endothelial growth factor (VEGF) secretion in glioblastoma multiforme cell lines - A clue to radioresistance? J Neurooncol 74 2005 99 103 (Pubitemid 41478904)
23. S. Pejavar, L.D. Wilson, and B.G. Haffty Regional nodal recurrence in breast cancer patients treated with conservative surgery and radiation therapy (BCS+RT) Int J Radiat Oncol Biol Phys 66 2006 1320 1327
24. B.G. Haffty, D. Fischer, and J.J. Fischer Regional nodal irradiation in the conservative treatment of breast cancer Int J Radiat Oncol Biol Phys 19 1990 859 865 (Pubitemid 20345152)
25. M.S. Moran, Q. Yang, and L.N. Harris Long-term outcomes and clinicopathologic differences of African-American versus white patients treated with breast conservation therapy for early-stage breast cancer Cancer 113 2008 2565 2574
26. R.L. Camp, L.A. Charette, and D.L. Rimm Validation of tissue microarray technology in breast carcinoma Lab Invest 80 2000 1943 1949 (Pubitemid 32012762)
27. D.L. Rimm, R.L. Camp, and L.A. Charette Tissue microarray: A new technology for amplification of tissue resources Cancer J 7 2001 24 31
28. H. Turley, P. Scott, and V. Watts Expression of VEGF in routinely fixed material using a new monoclonal J Pathol 186 1998 313 318 (Pubitemid 28494361)
29. B.D. Smith, G.L. Smith, and D. Carter Prognostic significance of vascular endothelial growth factor protein levels in oral and oropharyngeal squamous cell carcinoma J Clin Oncol 18 2000 2046 2052 (Pubitemid 30324357)
30. M. Toi, K. Inada, and S. Hoshina Vascular endothelial growth factor and platelet-derived endothelial cell growth factor are frequently coexpressed in highly vascularized human breast cancer Clin Cancer Res 1 1995 961 964
31. B.A. Jones, S.V. Kasl, and C.L. Howe African-American/white differences in breast carcinoma: p53 alterations and other tumor characteristics Cancer 101 2004 1293 1301 (Pubitemid 39180384)
32. L.A. Newman Breast carcinoma in African-American and white women: Application of molecular biology to understand outcome disparities Cancer 101 2004 1261 1263 (Pubitemid 39180380)
33. L.A. Carey, C.M. Perou, and C.A. Livasy Race, breast cancer subtypes, and survival in the Carolina Breast Cancer study JAMA 295 2006 2492 2503
34. Y. Wu, L. Saldana, and R. Chillar Plasma vascular endothelial growth factor is useful in assessing progression of breast cancer post surgery and during adjuvant treatment Int J Oncol 20 2002 509 516
35. B. Linderholm, B. Tavelin, and K. Grankvist Does vascular endothelial growth factor (VEGF) predict local relapse and survival in radiotherapy-treated node-negative breast cancer? Br J Cancer 81 1999 727 732 (Pubitemid 29458873)
36. P. Manders, F.C.G.J. Sweep, and V.C.G. Tjan-Heijnen Vascular endothelial growth factor independently predicts the efficacy of postoperative radiotherapy in node-negative breast cancer patients Clin Cancer Res 9 2003 6363 6370 (Pubitemid 38031821)
37. C. Feng, L. Wang, and L. Jiao Expression of p53, inducible nitric oxide synthase and vascular endothelial growth factor in gastric precancerous and cancerous lesions: Correlation with clinical features BMC Cancer 2 2002 8
38. D. Santini, B. Vincenzi, and G. Perrone Vascular endothelial growth factor (VEGF) expression is not associated with prognosis in patients with radically resected ampullary carcinoma Ann Oncol 16 2005 1847 1848 (Pubitemid 41631253)
39. I. Kostopoulos, P. Arapantoni-Dadioti, and H. Gogas Evaluation of the prognostic value of HER-2 and VEGF in breast cancer patients participating in a randomized study with dose-dense sequential adjuvant chemotherapy Breast Cancer Res Treatm 96 2006 251 261
40. Available from: www.nsabp.pitt.edu/B40-Protocol-Brochure.pdf.
41. Available from: www.roche-trials.com/patient/trials/trial110789.html.
42. Available from: www.clinicaltrials.gov/ct2/show/NCT00625898.